7 results
Systemic Lupus Erythematosus (SLE) - Diagnosis and Management Summary
 • Epidemiology: 10-180/100,000, Typically Age 20-40, F:M
Systemic Lupus Erythematosus ... Diagnosis and Management ... , oral ulcers, Lupus ... life-threatening • Treatment ... #Summary #rheumatology
Drug Induced Lupus vs SLE
Drug Induced Lupus (DIL):
 • Epidemiology: -10% of all lupus cases, drug-dependent,
constitutional symptoms • Treatment ... life-threatening • Treatment ... Usual therapeutic management ... comparison #table #rheumatology ... #diagnosis #management
IDSA Recommendations for Preventing and Treating Toxoplasma gondii Encephalitis in HIV-AIDS
Indications for Initiating Primary Prophylaxis:
 •
Toxoplasma IgG positive ... patients with CD4 ... IDSA #Prevention #Treatment ... #opportunistic ... infections #HIVAIDS #management
Drug Induced Lupus (DIL)
 • Epidemiology: -10% of all lupus cases, drug-dependent, 4:1 to 1:1 F:M
Anti-dsDNA - Rarely positive ... Anti-histone - Positive ... #DIL #rheumatology ... #diagnosis #treatment ... #management
IDSA Recommendations for Treating Coccidiodomycosis in HIV-AIDS
Treating Mild Infections (Such As Focal Pneumonia or asymptomatic patients
patients with positive ... serology and CD4 ... IDSA #Prevention #Treatment ... #management #opportunistic ... infections #HIVAIDS #pharmacology
Sjogren's Syndrome Overview

Epidemiology:
• F > M: 9:1
• 5-6th Decades (can be any age)

Autoimmune exocrinopathy multisystemic disease
/aggregate) of CD4 ... Adenocarcinoma Treatment ... lubricants • Pharmacologic ... Sjogrens #Syndrome #Rheumatology ... #Diagnosis #Management
Anti-NXP-2 Dermatomyositis

What?
DM with generalized subcutaneous edema
Pts have more myalgias, more severe weakness, and an increased prevalence
NXP-2 antibody positive ... of anti-NXP-2-positive ... patients Treatment ... Dermatomyositis #diagnosis #management ... #rheumatology #